JP2012529296A5 - - Google Patents

Download PDF

Info

Publication number
JP2012529296A5
JP2012529296A5 JP2012515080A JP2012515080A JP2012529296A5 JP 2012529296 A5 JP2012529296 A5 JP 2012529296A5 JP 2012515080 A JP2012515080 A JP 2012515080A JP 2012515080 A JP2012515080 A JP 2012515080A JP 2012529296 A5 JP2012529296 A5 JP 2012529296A5
Authority
JP
Japan
Prior art keywords
xten
fusion protein
seq
sequence
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012515080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012529296A (ja
JP5805634B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2010/023106 external-priority patent/WO2010091122A1/en
Application filed filed Critical
Priority claimed from PCT/US2010/037849 external-priority patent/WO2010144502A2/en
Publication of JP2012529296A publication Critical patent/JP2012529296A/ja
Publication of JP2012529296A5 publication Critical patent/JP2012529296A5/ja
Application granted granted Critical
Publication of JP5805634B2 publication Critical patent/JP5805634B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012515080A 2009-06-08 2010-06-08 成長ホルモンポリペプチド並びにその作成及び使用方法 Expired - Fee Related JP5805634B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US18511209P 2009-06-08 2009-06-08
US61/185,112 2009-06-08
US23683609P 2009-08-25 2009-08-25
US61/236,836 2009-08-25
US28095509P 2009-11-10 2009-11-10
US61/280,955 2009-11-10
USPCT/US2010/023106 2010-02-03
US12/699,761 2010-02-03
PCT/US2010/023106 WO2010091122A1 (en) 2009-02-03 2010-02-03 Extended recombinant polypeptides and compositions comprising same
US12/699,761 US8673860B2 (en) 2009-02-03 2010-02-03 Extended recombinant polypeptides and compositions comprising same
PCT/US2010/037849 WO2010144502A2 (en) 2009-06-08 2010-06-08 Growth hormone polypeptides and methods of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015068675A Division JP2015124222A (ja) 2009-06-08 2015-03-30 成長ホルモンポリペプチド並びにその作成及び使用方法

Publications (3)

Publication Number Publication Date
JP2012529296A JP2012529296A (ja) 2012-11-22
JP2012529296A5 true JP2012529296A5 (cg-RX-API-DMAC7.html) 2013-08-15
JP5805634B2 JP5805634B2 (ja) 2015-11-04

Family

ID=43309446

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012515080A Expired - Fee Related JP5805634B2 (ja) 2009-06-08 2010-06-08 成長ホルモンポリペプチド並びにその作成及び使用方法
JP2015068675A Withdrawn JP2015124222A (ja) 2009-06-08 2015-03-30 成長ホルモンポリペプチド並びにその作成及び使用方法
JP2016151272A Withdrawn JP2016185171A (ja) 2009-06-08 2016-08-01 成長ホルモンポリペプチド並びにその作成及び使用方法
JP2017181582A Expired - Fee Related JP6543668B2 (ja) 2009-06-08 2017-09-21 成長ホルモンポリペプチド並びにその作成及び使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015068675A Withdrawn JP2015124222A (ja) 2009-06-08 2015-03-30 成長ホルモンポリペプチド並びにその作成及び使用方法
JP2016151272A Withdrawn JP2016185171A (ja) 2009-06-08 2016-08-01 成長ホルモンポリペプチド並びにその作成及び使用方法
JP2017181582A Expired - Fee Related JP6543668B2 (ja) 2009-06-08 2017-09-21 成長ホルモンポリペプチド並びにその作成及び使用方法

Country Status (26)

Country Link
EP (2) EP3278813A1 (cg-RX-API-DMAC7.html)
JP (4) JP5805634B2 (cg-RX-API-DMAC7.html)
KR (1) KR101813727B1 (cg-RX-API-DMAC7.html)
CN (2) CN103140236B (cg-RX-API-DMAC7.html)
AU (1) AU2010258892B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1010880A2 (cg-RX-API-DMAC7.html)
CA (1) CA2764105A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011003121A1 (cg-RX-API-DMAC7.html)
DK (1) DK2440241T3 (cg-RX-API-DMAC7.html)
EA (1) EA030619B1 (cg-RX-API-DMAC7.html)
ES (1) ES2643641T3 (cg-RX-API-DMAC7.html)
HK (1) HK1250215A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20171644T1 (cg-RX-API-DMAC7.html)
HU (1) HUE037249T2 (cg-RX-API-DMAC7.html)
IL (1) IL216680A (cg-RX-API-DMAC7.html)
LT (1) LT2440241T (cg-RX-API-DMAC7.html)
MX (2) MX354555B (cg-RX-API-DMAC7.html)
NO (1) NO2440241T3 (cg-RX-API-DMAC7.html)
NZ (2) NZ621868A (cg-RX-API-DMAC7.html)
PE (1) PE20121539A1 (cg-RX-API-DMAC7.html)
PL (1) PL2440241T3 (cg-RX-API-DMAC7.html)
PT (1) PT2440241T (cg-RX-API-DMAC7.html)
SG (2) SG176726A1 (cg-RX-API-DMAC7.html)
SI (1) SI2440241T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010144502A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201200123B (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプramのチエツク方法
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
JP5843357B2 (ja) 2009-02-03 2016-01-13 アムニクス オペレーティング インコーポレイテッド 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP3278813A1 (en) * 2009-06-08 2018-02-07 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
NZ596778A (en) 2009-06-08 2013-11-29 Amunix Operating Inc Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
JP2013502458A (ja) 2009-08-24 2013-01-24 アムニクス オペレーティング インコーポレイテッド 凝固第vii因子組成物ならびにそれを製造および使用する方法
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
EA024755B1 (ru) 2010-05-21 2016-10-31 ИксЭль-ПРОТЕИН ГМБХ Биосинтетические нерегулярные спиральные полипептиды пролина/аланина и их применения
EP3527218A1 (en) 2011-06-10 2019-08-21 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
KR102212098B1 (ko) 2012-01-12 2021-02-03 바이오버라티브 테라퓨틱스 인크. 키메라 인자 viii 폴리펩티드들과 이의 용도
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第viii因子タンパク質
MX369862B (es) 2012-02-15 2019-11-25 Bioverativ Therapeutics Inc Composiciones del factor viii y metodos para hacerlas y usarlas.
AU2013226090B2 (en) 2012-02-27 2018-03-08 Amunix Operating Inc. XTEN conjugate compositions and methods of making same
HK1208629A1 (en) * 2012-06-05 2016-03-11 Amunix Operating Inc. Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
EP4079316A1 (en) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Procoagulant compounds
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. キメラ性凝固因子
EA201792485A3 (ru) * 2012-07-11 2019-03-29 Амуникс Оперэйтинг Инк. Комплекс фактора viii с xten и белком-фактором фон виллебранда, и его применение (варианты)
PL2956477T5 (pl) 2013-02-15 2024-05-27 Bioverativ Therapeutics Inc. Zoptymalizowany gen czynnika viii
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
US20160251408A1 (en) 2013-06-28 2016-09-01 Biogen Ma Inc. Thrombin cleavable linker with xten and its uses thereof
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子viii-xten融合物及其用途
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
MY204756A (en) 2014-01-10 2024-09-11 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
KR20170062490A (ko) 2014-09-26 2017-06-07 바이엘 파마 악티엔게젤샤프트 안정화된 아드레노메둘린 유도체 및 그의 용도
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
US20180125988A1 (en) * 2014-11-11 2018-05-10 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3383361B1 (en) * 2015-12-03 2021-08-11 DNA Essence GmbH Oligonucleotides in food, beverage, cosmetic and medicinal formulations
RS63548B1 (sr) 2016-02-01 2022-09-30 Bioverativ Therapeutics Inc Optimizovani geni faktora viii
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
KR20250040746A (ko) 2017-08-09 2025-03-24 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
MX2020006619A (es) 2017-12-21 2020-09-14 Amunix Pharmaceuticals Inc Segmentos de liberacion y composiciones vinculantes que comprenden los mismos.
CN111918674A (zh) 2018-02-01 2020-11-10 比奥维拉迪维治疗股份有限公司 表达因子viii的慢病毒载体的用途
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
LT3793588T (lt) 2018-05-18 2025-06-25 Bioverativ Therapeutics Inc. Hemofilijos a gydymo būdai
BR112020026512A2 (pt) 2018-07-03 2021-04-06 Bristol-Myers Squibb Company Formulações de fgf-21
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
US20220089704A1 (en) 2018-10-29 2022-03-24 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
SG11202105880TA (en) 2018-12-06 2021-07-29 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor ix
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
IL292863A (en) 2019-11-13 2022-07-01 Amunix Pharmaceuticals Inc Barcoded xanthan polypeptides and their compositions, and methods for their preparation and use
BR112022026127A2 (pt) 2020-06-24 2023-01-17 Bioverativ Therapeutics Inc Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
AU2021297984C1 (en) 2020-06-25 2025-12-11 Amunix Pharmaceuticals, Inc. HER-2 targeted bispecific compositions and methods for making and using the same
TW202323274A (zh) 2021-08-23 2023-06-16 美商百歐維拉提夫治療公司 優化因子viii基因
JP2024534123A (ja) 2021-08-23 2024-09-18 バイオベラティブ セラピューティクス インコーポレイテッド バキュロウイルス発現システム
CN113880954B (zh) * 2021-09-29 2024-05-14 江苏大学 一种重组人生长激素及其构建方法和应用
AU2022355088A1 (en) 2021-09-30 2024-05-16 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
CN116554343B (zh) * 2022-01-30 2024-07-12 领诺(上海)医药科技有限公司 一种长效重组人生长激素及其应用
WO2024168279A2 (en) 2023-02-10 2024-08-15 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same
KR20250166225A (ko) 2023-04-17 2025-11-27 아뮤닉스 파마슈티컬스, 인크. 표피 성장 인자 수용체를 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
WO2025122957A1 (en) 2023-12-08 2025-06-12 Amunix Pharmaceuticals, Inc. Protease activatable cytokines and methods for making and using the same

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4284444A (en) 1977-08-01 1981-08-18 Herculite Protective Fabrics Corporation Activated polymer materials and process for making same
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4898830A (en) 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4398908A (en) 1980-11-28 1983-08-16 Siposs George G Insulin delivery system
US4435173A (en) 1982-03-05 1984-03-06 Delta Medical Industries Variable rate syringe pump for insulin delivery
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
EP0190262B1 (en) 1984-07-24 1990-12-27 Key Pharmaceuticals, Inc. Adhesive transdermal dosage layer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US4933185A (en) 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US4976696A (en) 1987-08-10 1990-12-11 Becton, Dickinson And Company Syringe pump and the like for delivering medication
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
JP2717808B2 (ja) 1988-08-10 1998-02-25 テルモ株式会社 シリンジポンプ
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
ES2038579T3 (es) 1989-04-28 1997-02-16 Rhein Biotech Proz & Prod Gmbh Celulas de levadura del genero schwanniomyces.
US5017378A (en) 1989-05-01 1991-05-21 The University Of Virginia Alumni Patents Foundation Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres
US5298022A (en) 1989-05-29 1994-03-29 Amplifon Spa Wearable artificial pancreas
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5318540A (en) 1990-04-02 1994-06-07 Pharmetrix Corporation Controlled release infusion device
US5492534A (en) 1990-04-02 1996-02-20 Pharmetrix Corporation Controlled release portable pump
US5176502A (en) 1990-04-25 1993-01-05 Becton, Dickinson And Company Syringe pump and the like for delivering medication
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
DK0929293T3 (da) 1996-08-23 2004-02-02 Sequus Pharm Inc Liposomer indeholdende en cisplatinforbindelse
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
SK283760B6 (sk) 1996-10-15 2004-01-08 The Liposome Company, Inc. Farmaceutický prostriedok na dopravu bioaktívnych látok
JP4863534B2 (ja) 1996-10-25 2012-01-25 スパーナス ファーマシューティカルズ インコーポレイテッド 可溶形態浸透用量送達システム
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
EP1563866B1 (en) 1998-02-05 2007-10-03 Biosense Webster, Inc. Intracardiac drug delivery
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
BR0008650B1 (pt) 1999-03-03 2010-12-28 dispositivo de transmissão via nasal.
US6183770B1 (en) 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
IN190699B (cg-RX-API-DMAC7.html) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
WO2002087621A1 (en) 2001-04-30 2002-11-07 Shire Laboratories Inc. Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
US6838093B2 (en) 2001-06-01 2005-01-04 Shire Laboratories, Inc. System for osmotic delivery of pharmaceutically active agents
KR100407467B1 (ko) 2001-07-12 2003-11-28 최수봉 리모컨 방식의 인슐린 자동주사기
AU2003237119A1 (en) * 2002-04-29 2003-11-17 Euro-Celtique S.A. Conformationally constrained peptides that bind the orl-1 receptor
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
SE0300959D0 (sv) * 2002-12-19 2003-04-02 Pharmacia Ab Methods for predicting therapeutic response to agents acting on the growth hormone receptor
US20090099031A1 (en) 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
AU2007223888A1 (en) * 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
BRPI0716261A2 (pt) * 2006-08-31 2013-08-06 Novartis Ag composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
EA021222B8 (ru) * 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
JP5843357B2 (ja) * 2009-02-03 2016-01-13 アムニクス オペレーティング インコーポレイテッド 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
EP3278813A1 (en) * 2009-06-08 2018-02-07 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same

Similar Documents

Publication Publication Date Title
JP2012529296A5 (cg-RX-API-DMAC7.html)
KR101651977B1 (ko) 장기 작용 폴리펩티드 및 그의 생산 및 투여 방법
JP5524049B2 (ja) 目的ペプチドの血漿中半減期延長作用を有するペプチド
ES2983610T3 (es) Hormona del crecimiento de acción prolongada y métodos para producir la misma
US8999670B2 (en) Long-acting polypeptides and methods of producing same
JP2012529297A5 (cg-RX-API-DMAC7.html)
US20130157953A1 (en) Treatment of cardiac conditions
HRP20171644T1 (hr) Polipeptidi hormona rasta kao i postupci za njihovu proizvodnju i uporabu
JP2016511752A5 (cg-RX-API-DMAC7.html)
JP2010518079A5 (cg-RX-API-DMAC7.html)
JP2016512213A5 (cg-RX-API-DMAC7.html)
JP2009525052A5 (cg-RX-API-DMAC7.html)
KR20150124955A (ko) 사람 성장 호르몬 유사체를 사용한 소아 성장 호르몬 결핍증의 치료 방법
JP2016518351A5 (cg-RX-API-DMAC7.html)
CN103408669A (zh) Glp-1类似物融合蛋白,及其制备方法和用途
CN109689086A (zh) 具有延长的血清半衰期的融合蛋白
WO2011031477A2 (en) Nucleolin-binding peptides, nucleolin-binding lytic peptides, fusion constructs and methods of making and using same
JP7445695B2 (ja) 長期活性型ポリペプチドならびに当該ポリペプチドの製造方法および投与方法
CN101967196A (zh) 一种干扰素融合蛋白及其制备和应用
JP2009510999A (ja) キメラ治療剤
Mak et al. Preparation of potent leptin receptor antagonists and their therapeutic use in mouse models of uremic cachexia and kidney fibrosis
JP2021505656A (ja) グルカゴン様ペプチド
CN106146667B (zh) 一种Exendin-4融合蛋白及其制备方法与用途
WO2015090234A1 (en) Improving pharmacokinetic profile for angiopoietin-2 inhibiting polypeptide or thymalfasin
HK40008897A (en) Long-acting growth hormone and methods of producing same